Management of residual mass in nonseminomatous germ cell tumors following chemotherapy-Reference-Cited by-同舟云学术

Management of residual mass in nonseminomatous germ cell tumors following chemotherapy

Published:2011-08 Issue:4 Volume:3 Page:163-171
ISSN:1756-2872
Container-title:Therapeutic Advances in Urology
language:en
Short-container-title:Therapeutic Advances in Urology

Author:

Daneshmand Siamak¹,Djaladat Hooman²,Nichols Craig³

Affiliation:

1. USC Institute of Urology, 1441 East Lake Avenue, Suite 7461, Los Angeles, CA 90033, USA

2. Urologic Oncology Fellow, Norris Comprehensive Cancer Center, USC Institute of Urology, Los Angeles, CA, USA

3. Testis Cancer Consortium Portland, OR, USA

Abstract

Advanced stage nonseminomatous testis cancer is commonly treated with chemotherapy and surgical resection. Patients with retroperitoneal residual masses >1cm following induction chemotherapy with normalized tumor markers should undergo a post-chemotherapy retroperitoneal lymph node dissection. Post chemotherapy retroperitoneal residual mass less than 1 cm with normal markers may be considered as complete response, although the possibility of residual teratoma and viable germ cell tumor are not definitively ruled out. Excellent long term disease free survival following surveillance may justify this option as the treatment of choice in this cohort of patients.

Publisher

SAGE Publications

Subject

Urology

Link

http://journals.sagepub.com/doi/pdf/10.1177/1756287211418721

Reference59 articles.

1. Surgery in testis cancer: laparoscopic and open techniques

2. Resection of postchemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumors

3. Complications of retroperitoneal lymph node dissection in testicular cancer: Primary and post-chemotherapy

4. Management of the post chemotherapy subcentimeter residual mass: the case for observation

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Suprahilar and Retrocrural Domains in RPLND for NSGCT Testis—Going Beyond Where the Light Touches!;Indian Journal of Surgical Oncology;2024-07-27

2. Consolidative radiation in partial responders/unresectable/recurrent disease after first-line/salvage chemotherapy in poor-risk nonseminomatous germ cell tumor prolongs survival: A new paradigm?;Journal of Cancer Research and Therapeutics;2022

3. Chemotherapeutic Protocols for the Treatment of Genitourinary Cancer;Chemotherapy Protocols and Infusion Sequence;2022

4. Post-chemotherapy modified template retroperitoneal lymph node dissection in patients with nonseminomatous germ cell tumours;Aktuelle Urologie;2021-11-03

5. Robotic post-chemotherapy retroperitoneal lymph node dissection with infrarenal cavectomy “Show me how”;Urology Video Journal;2021-09